Targeted Therapies in Neuroendocrine Tumors
0 Views
administrator
07/13/23
The clinical benefit of targeted therapies in neuroendocrine tumors (NETs) has primarily been restricted to the pancreatic type. However, clinical trials are currently under way examining the mTOR inhibitor everolimus in a broader patient population.
For more from this discussion, visit http://www.onclive.com/peer-exchange/nets
-
Category
Show more
Facebook Comments
No comments found